GBIO Profile
Generation Bio Co (GBIO) is a biotechnology company that focuses on developing gene therapies for patients with rare and prevalent diseases. The company's proprietary GeneWave technology allows for the durable and regulated delivery of genetic medicines, including large and complex genes. Generation Bio's lead product candidate is in development for the treatment of transthyretin amyloidosis (ATTR), a rare genetic disease characterized by the buildup of amyloid deposits in tissues throughout the body. The company is also developing product candidates for other rare and prevalent diseases. Generation Bio is headquartered in Cambridge, Massachusetts and was founded in 2016. The company went public in 2020.
|
